VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N,N-Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton…


Previous articlePTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh Bartch of Mydecine Innovations Group
Next articlePsychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds